Clinicopathologic study of squamous cell carcinoma of the ovary

Characteristics and Treatment Outcomes of Patients with Malignant Transformation Arising from Mature Cystic Teratoma of the Ovary: Experience at a Single Institution

“…From several studies, the median age at diagnosis of malignant transformation of mature cystic teratoma of the ovary was 54-61.5 years, and tended to be older than that of its benign counterpart and most of them were in postmenopausal period (Kashimura et al, 1989;Kikkawa et al 1998;Rim et al, 2006;Dos Santos et al, 2007). That is not consistent with our study which finds that most of the patients are in premenopausal state and the median age at diagnosis is much younger (41.2 years).…”

“…Multimodality therapy including aggressive cytoreduction followed by chemotherapy and/or radiation therapy has been recommended by several authors (Peterson, 1957;Amerigo et al, 1979;Stamp, 1983;Hirakawa et al, 1989;Kashimura et al, 1989;Pins et al, 1996;Sakuma et al, 2010;Chen et al, 2012). From our study, we could perform optimal cytoreduction in most of the patients and only two patients who were in stage IIIc could not be optimally debulked.…”

“…In general, most of the mature cystic teratoma of the ovary patients present with symptoms. The most common symptoms were abdominal pain, palpable mass and abdominal distension (Stamp et al, 1983;Hirakawa et al, 1989;Kashimura et al, 1989;Tseng et al, 1996). Most of our patients also presented with palpable mass and all of our patients were scanned with lower abdominal ultrasonography but unable to find any benefit for diagnosis of malignant transformation.…”

Primary Squamous-Cell Carcinoma of the Ovary: A Report of 2 Cases and Review of the Literature

“…These are listed in Table 1. [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] The clinical presentation of SCC is not largely different from other types of ovarian malignancies. Most patients presented with lower-abdominal fullness, pain, or abdominal masses.…”

Tératome cancérisé de l’ovaire

“…La survie à cinq ans est de l'ordre de 50 % pour les carcinomes épidermoïdes stade clinique I. Ce taux chute à 25 % pour les tumeurs stade II et à 12 % pour les tumeurs stade III [9].…”